{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Aucatzyl"},{"type":"CodeName","name":"AUTO 1"},{"type":"CodeName","name":"AUTO1"},{"type":"CodeName","name":"AUTO-1"},{"type":"Synonym","name":"AUTO1 CAR-T cells"},{"type":"Synonym","name":"autologous anti-CD19 CAR T cells AUTO1"},{"type":"LexicalVariant","name":"autologous anti-CD19 chimeric antigen receptor T cells AUTO1"},{"type":"Synonym","name":"autologous anti-CD19 chimeric antigen receptor T lymphocytes AUTO1"},{"type":"Synonym","name":"autologous CD19-targeted CAR T cells AUTO1"},{"type":"Synonym","name":"CD19CAR T cells AUTO1"},{"type":"Synonym","name":"CD19CAT-41BBZ CAR T cells AUTO1"},{"type":"Synonym","name":"obe-cel"}],"definition":{"html":"A preparation of autologous T lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, obecabtagene autoleucel target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate compared with FMC63-41BBz CAR. This may minimize cytokine release and reduce toxicities, and enhance persistence of the CAR T cells.","text":"A preparation of autologous T lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, obecabtagene autoleucel target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate compared with FMC63-41BBz CAR. This may minimize cytokine release and reduce toxicities, and enhance persistence of the CAR T cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/obecabtagene-autoleucel","text":"Obecabtagene Autoleucel"},"nciConceptId":"C172746","nciConceptName":"Obecabtagene Autoleucel","termId":801949,"name":"obecabtagene autoleucel","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"obecabtagene-autoleucel"}],"links":null}